226 related articles for article (PubMed ID: 22761294)
1. Human papillomavirus (HPV) L1 and L1-L2 virus-like particle-based multiplex assays for measurement of HPV virion antibodies.
Hernandez BY; Ton T; Shvetsov YB; Goodman MT; Zhu X
Clin Vaccine Immunol; 2012 Sep; 19(9):1348-52. PubMed ID: 22761294
[TBL] [Abstract][Full Text] [Related]
2. Correlation between cervical HPV DNA detection and HPV16 seroreactivity measured with L1-only and L1+L2 viral capsid antigens.
Trevisan A; Candeias JMG; Thomann P; Villa LL; Franco EL; Trottier H; The Ludwig-McGill Study Group
J Med Microbiol; 2020 Jul; 69(7):960-970. PubMed ID: 32510304
[No Abstract] [Full Text] [Related]
3. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
4. Type-specific and cross-reactive antibodies induced by human papillomavirus 31 L1/L2 virus-like particles.
Xu Y; Wang Q; Han Y; Song G; Xu X
J Med Microbiol; 2007 Jul; 56(Pt 7):907-913. PubMed ID: 17577054
[TBL] [Abstract][Full Text] [Related]
5. Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.
Wang JW; Jagu S; Wang C; Kitchener HC; Daayana S; Stern PL; Pang S; Day PM; Huh WK; Roden RB
PLoS One; 2014; 9(7):e101576. PubMed ID: 24999962
[TBL] [Abstract][Full Text] [Related]
6. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16.
Kirnbauer R; Hubbert NL; Wheeler CM; Becker TM; Lowy DR; Schiller JT
J Natl Cancer Inst; 1994 Apr; 86(7):494-9. PubMed ID: 8133532
[TBL] [Abstract][Full Text] [Related]
7. Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV).
Huber B; Schellenbacher C; Shafti-Keramat S; Jindra C; Christensen N; Kirnbauer R
PLoS One; 2017; 12(1):e0169533. PubMed ID: 28056100
[TBL] [Abstract][Full Text] [Related]
8. Comparison of a VLP-based and GST-L1-based multiplex immunoassay to detect vaccine-induced HPV-specific antibodies in first-void urine.
Pattyn J; Panicker G; Willhauck-Fleckenstein M; Van Keer S; Téblick L; Pieters Z; Tjalma WAA; Matheeussen V; Van Damme P; Waterboer T; Unger ER; Vorsters A
J Med Virol; 2020 Dec; 92(12):3774-3783. PubMed ID: 32266996
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.
Robbins HA; Waterboer T; Porras C; Kemp TJ; Pawlita M; Rodriguez AC; Wacholder S; Gonzalez P; Schiller JT; Lowy DR; Esser M; Matys K; Poncelet S; Herrero R; Hildesheim A; Pinto LA; Safaeian M
Hum Vaccin Immunother; 2014; 10(10):2965-74. PubMed ID: 25483632
[TBL] [Abstract][Full Text] [Related]
10. Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus.
Robbins HA; Li Y; Porras C; Pawlita M; Ghosh A; Rodriguez AC; Schiffman M; Wacholder S; Kemp TJ; Gonzalez P; Schiller J; Lowy D; Esser M; Matys K; Quint W; van Doorn LJ; Herrero R; Pinto LA; Hildesheim A; Waterboer T; Safaeian M
BMC Infect Dis; 2014 Mar; 14():120. PubMed ID: 24588945
[TBL] [Abstract][Full Text] [Related]
11. Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination.
Zhao H; Lin ZJ; Huang SJ; Li J; Liu XH; Guo M; Zhang J; Xia NS; Pan HR; Wu T; Li CG
Hum Vaccin Immunother; 2014; 10(3):740-6. PubMed ID: 24384608
[TBL] [Abstract][Full Text] [Related]
12. RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer.
Olczak P; Matsui K; Wong M; Alvarez J; Lambert P; Christensen ND; Hu J; Huber B; Kirnbauer R; Wang JW; Roden RBS
J Virol; 2022 Jul; 96(13):e0056622. PubMed ID: 35703545
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: correlation with virus-like particle IgG concentration.
Bryan JT; Jansen KU; Lowe RS; Fife KH; McClowry T; Glass D; Brown DR
J Med Virol; 1997 Nov; 53(3):185-8. PubMed ID: 9365880
[TBL] [Abstract][Full Text] [Related]
14. HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase.
Sehr P; Müller M; Höpfl R; Widschwendter A; Pawlita M
J Virol Methods; 2002 Oct; 106(1):61-70. PubMed ID: 12367730
[TBL] [Abstract][Full Text] [Related]
15. Polymer-based enzyme-linked immunosorbent assay using human papillomavirus type 16 (HPV16) virus-like particles detects HPV16 clade-specific serologic responses.
Studentsov YY; Ho GY; Marks MA; Bierman R; Burk RD
J Clin Microbiol; 2003 Jul; 41(7):2827-34. PubMed ID: 12843008
[TBL] [Abstract][Full Text] [Related]
16. VLP Production from Recombinant L1/L2 HPV-16 Protein Expressed in Pichia Pastoris.
Sanchooli A; Aghaiypour K; Kiasari BA; Samarbaf-Zadeh A; Ghadiri A; Makvandi M
Protein Pept Lett; 2018; 25(8):783-790. PubMed ID: 30091403
[TBL] [Abstract][Full Text] [Related]
17. Antibody Competition Reveals Surface Location of HPV L2 Minor Capsid Protein Residues 17-36.
Bywaters SM; Brendle SA; Tossi KP; Biryukov J; Meyers C; Christensen ND
Viruses; 2017 Nov; 9(11):. PubMed ID: 29125554
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses.
Schellenbacher C; Kwak K; Fink D; Shafti-Keramat S; Huber B; Jindra C; Faust H; Dillner J; Roden RBS; Kirnbauer R
J Invest Dermatol; 2013 Dec; 133(12):2706-2713. PubMed ID: 23752042
[TBL] [Abstract][Full Text] [Related]
19. Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity.
Zhao Q; Modis Y; High K; Towne V; Meng Y; Wang Y; Alexandroff J; Brown M; Carragher B; Potter CS; Abraham D; Wohlpart D; Kosinski M; Washabaugh MW; Sitrin RD
Virol J; 2012 Feb; 9():52. PubMed ID: 22356831
[TBL] [Abstract][Full Text] [Related]
20. Optimization of RG1-VLP vaccine performance in mice with novel TLR4 agonists.
Zacharia A; Harberts E; Valencia SM; Myers B; Sanders C; Jain A; Larson NR; Middaugh CR; Picking WD; Difilippantonio S; Kirnbauer R; Roden RB; Pinto LA; Shoemaker RH; Ernst RK; Marshall JD
Vaccine; 2021 Jan; 39(2):292-302. PubMed ID: 33309485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]